Yoshiya Tanaka

54.9k total citations · 14 hit papers
1.1k papers, 30.4k citations indexed

About

Yoshiya Tanaka is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Yoshiya Tanaka has authored 1.1k papers receiving a total of 30.4k indexed citations (citations by other indexed papers that have themselves been cited), including 667 papers in Rheumatology, 288 papers in Immunology and 246 papers in Genetics. Recurrent topics in Yoshiya Tanaka's work include Rheumatoid Arthritis Research and Therapies (428 papers), Systemic Lupus Erythematosus Research (288 papers) and Chronic Lymphocytic Leukemia Research (202 papers). Yoshiya Tanaka is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (428 papers), Systemic Lupus Erythematosus Research (288 papers) and Chronic Lymphocytic Leukemia Research (202 papers). Yoshiya Tanaka collaborates with scholars based in Japan, United States and United Kingdom. Yoshiya Tanaka's co-authors include Shingo Nakayamada, Yosuke Okada, Kazuyoshi Saito, Tsutomu Takeuchi, Stephen Shaw, Kunihiro Yamaoka, Kazuhisa Nakano, Hisashi Yamanaka, Satoshi Kubo and David Adams and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Yoshiya Tanaka

1.1k papers receiving 29.7k citations

Hit Papers

Trial of Anifrolumab in A... 1992 2026 2003 2014 2019 1993 2017 1992 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
    2019 778 citations Yoshiya Tanaka et al. profile →
  2. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ
    1993 774 citations Yoshiya Tanaka et al. profile →
  3. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    2017 621 citations Peter C. Taylor, Michael E. Weinblatt et al. profile →
  4. Lymphocyte interactions with endothelial cells
    1992 601 citations Yoshiya Tanaka et al. profile →
  5. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Yoshiya Tanaka et al. profile →
  6. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Yoshiya Tanaka et al. profile →
  7. Janus kinase inhibitors in autoimmune diseases
    2013 354 citations Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →
  8. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
    2022 320 citations Yoshiya Tanaka, Shingo Nakayamada et al. profile →
  9. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
    2017 302 citations Yoshiya Tanaka, Jeffrey R. Curtis et al. Annals of the Rheumatic Diseases profile →
  10. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    2019 260 citations Paul Emery, Yoshiya Tanaka et al. profile →
  11. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
    2020 180 citations Yoshiya Tanaka, Gerd R Burmester et al. Annals of the Rheumatic Diseases profile →
  12. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Bernard Combe, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →
  13. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
    2023 124 citations Gerd R Burmester, Yoshiya Tanaka et al. RMD Open profile →
  14. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
    2023 89 citations Yoshiya Tanaka et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Yoshiya Tanaka 14.5k 9.6k 5.7k 5.4k 5.2k 1.1k 30.4k
Paul P. Tak 14.0k 1.0× 11.8k 1.2× 8.6k 1.5× 4.5k 0.8× 4.4k 0.8× 459 33.5k
Ravinder N. Maini 17.2k 1.2× 10.2k 1.1× 5.1k 0.9× 4.7k 0.9× 6.0k 1.2× 271 31.4k
Gary S. Firestein 11.4k 0.8× 10.2k 1.1× 12.1k 2.1× 5.9k 1.1× 3.3k 0.6× 308 33.7k
René E. M. Toes 12.6k 0.9× 15.6k 1.6× 6.5k 1.1× 5.0k 0.9× 2.2k 0.4× 490 30.9k
Frank C. Arnett 24.3k 1.7× 9.2k 1.0× 4.2k 0.7× 2.5k 0.5× 5.6k 1.1× 196 37.7k
Josef S Smolen 12.5k 0.9× 5.5k 0.6× 4.8k 0.8× 3.0k 0.6× 3.8k 0.7× 342 20.7k
Mark C. Genovese 14.1k 1.0× 8.5k 0.9× 2.1k 0.4× 3.4k 0.6× 6.5k 1.2× 317 22.7k
Dennis J. McShane 27.6k 1.9× 10.6k 1.1× 3.9k 0.7× 2.2k 0.4× 5.1k 1.0× 31 39.4k
Peter Valent 8.6k 0.6× 16.7k 1.7× 9.7k 1.7× 4.3k 0.8× 9.6k 1.9× 900 40.5k
Ferdinand C. Breedveld 15.2k 1.0× 5.4k 0.6× 2.3k 0.4× 2.3k 0.4× 5.4k 1.0× 182 21.9k

Countries citing papers authored by Yoshiya Tanaka

Since Specialization
Citations

This map shows the geographic impact of Yoshiya Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiya Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiya Tanaka more than expected).

Fields of papers citing papers by Yoshiya Tanaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiya Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiya Tanaka. The network helps show where Yoshiya Tanaka may publish in the future.

Co-authorship network of co-authors of Yoshiya Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiya Tanaka. A scholar is included among the top collaborators of Yoshiya Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiya Tanaka. Yoshiya Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanaka, Yoshiya, Tatsuya Atsumi, Masato Okada, et al.. (2025). Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. Modern Rheumatology. 35(3). 458–469. 1 indexed citations
2.
Nakayamada, Shingo, Satoshi Kubo, Yusuke Miyazaki, et al.. (2025). Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus. RMD Open. 11(1). e005122–e005122. 1 indexed citations
3.
4.
Sada, Ken‐ei, Takako Miyamae, Kayoko Kaneko, et al.. (2024). Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review. Modern Rheumatology. 35(1). 88–93.
5.
Kobayashi, Hiroki, Yusuke Miyazaki, Shingo Nakayamada, et al.. (2024). Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry. Lara D. Veeken. 64(5). 2403–2410. 1 indexed citations
6.
Smolen, Josef S, Peter C. Taylor, Yoshiya Tanaka, et al.. (2024). Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. Lara D. Veeken. 63(11). 3015–3024. 6 indexed citations
7.
Tanaka, Yoshiya, Tsutomu Takeuchi, Tatsuya Atsumi, et al.. (2023). Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses. Rheumatology and Therapy. 10(6). 1399–1415. 2 indexed citations
8.
Tanaka, Yoshiya. (2023). A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. Inflammation and Regeneration. 43(1). 3–3. 12 indexed citations
9.
Hase, Ryota, Daisuke Suzuki, Cynthia de Luise, et al.. (2023). Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan. BMC Infectious Diseases. 23(1). 653–653. 1 indexed citations
10.
Buch, Maya H, Bernard Combe, José A. Gómez‐Puerta, et al.. (2023). OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions. Lara D. Veeken. 62(Supplement_2). 1 indexed citations
11.
Takeuchi, Tsutomu, Yukihiro Chino, Yoko Mano, et al.. (2023). Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis. The Journal of Clinical Pharmacology. 64(4). 418–427. 2 indexed citations
12.
Emery, Paul, Yoshiya Tanaka, Vivian P. Bykerk, et al.. (2023). Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. Rheumatology and Therapy. 10(3). 707–727. 6 indexed citations
13.
14.
Yamagata, Kaoru, S. Iwata, Koshiro Sonomoto, et al.. (2022). Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. PLoS ONE. 17(12). e0279584–e0279584. 2 indexed citations
15.
Tanaka, Yoshiya, et al.. (2020). Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases. SHILAP Revista de lepidopterología.
16.
17.
18.
Allaart, C.F., Linda Dirven, Shintaro Hirata, et al.. (2011). A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study. Data Archiving and Networked Services (DANS). 1 indexed citations
19.
Zeki, Kazuya, Yoshiya Tanaka, Isao Morimoto, et al.. (1998). Induction of expression of MHC‐class‐II antigen on human thyroid carcinoma by wild‐type p53. International Journal of Cancer. 75(3). 391–395. 3 indexed citations
20.
Zeki, Kazuya, Yoshiya Tanaka, Isao Morimoto, et al.. (1998). Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. International Journal of Cancer. 75(3). 391–395. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul P. Tak Breakdown of academic impact, for papers by Ravinder N. Maini Breakdown of academic impact, for papers by Gary S. Firestein Breakdown of academic impact, for papers by René E. M. Toes Breakdown of academic impact, for papers by Frank C. Arnett Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Mark C. Genovese Breakdown of academic impact, for papers by Dennis J. McShane Breakdown of academic impact, for papers by Peter Valent Breakdown of academic impact, for papers by Ferdinand C. Breedveld
Rankless by CCL
2026